A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease
Latest Information Update: 21 Oct 2024
At a glance
- Drugs ALN HTT02 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 15 Oct 2024 Planned initiation date changed from 30 Sep 2024 to 31 Oct 2024.
- 09 Sep 2024 New trial record